Powered by
ANN ARBOR–HistoSonics, developers of non-invasive sonic beam therapy called histotripsy, announced that the U.S. Food and Drug Administration has approved the company sponsored #HOPE4KIDNEY Trial, which is designed to evaluate the …
ANN ARBOR—HistoSonics Inc., developer of a non-invasive sonic beam therapy, announced that it has raised $85 million in a financing led by Johnson & Johnson Innovation Inc., with participation from …
ANN ARBOR–HistoSonics Inc., the developer and manufacturer of a completely non-invasive platform and proprietary sonic beam therapy, announced the publication of results from their prospective Phase I clinical trial, conducted …
ANN ARBOR—Officials at HistoSonics, developer of novel ultrasound therapies, announced today that the first patient has been treated as part of the company’s #HOPE4LIVER Europe Trial, which was approved by …
ANN ARBOR—HistoSonics, developer of a non-invasive sonic beam therapy, announced today the treatment of the first patient in the #HOPE4LIVER US Study. The investigational device study was approved by the …
ANN ARBOR—HistoSonics Inc. announced that it had received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to begin a clinical trial of its new technology, …
MINNEAPOLIS—HistoSonics, a biotech startup developing a robotic ultrasound medical treatment system, announced that it had closed $40 million in a Series C-1 funding. Company officials said the round was led …